Жиль Т. Д. Роль вазодилатирующих β-адреноблокаторов в терапии пациентов с осложненной гипертензией: фокус на небиволол. Кардиоваскулярная терапия и профилактика. 2011;10(6):94-98.
1. Krumholz HM, Radford MJ, Wang Y, et al. National use and effectiveness of β-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 1998; 280: 623-9.
2. Ko DT, Hebert PR, Coffey CS, et al. β-Blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288: 351-7.
3. Fogari R, Zoppi A, Corradi L, et al. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Am J Hypertens 1998; 11: 1244-7.
4. Elliott WJ, Meyer PM. One-year discontinuation rates of antihypertensive drugs in clinical practice: a network meta-analysis. J Clin Hypertens 2007; 9(suppl A): A210.
5. Weber MA. The role of new β-blockers in treating cardiovascular disease. Am J Hypertens 2005; 18(pt 2): 169S-76.
6. Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep 2007; 9: 269-77.
7. Bermúdez V, Bermúdez F, Acosta G, et al. Molecular mechanisms of endothelial dysfunction: from nitric oxide synthesis to ADMA inhibition. Am J Ther 2008; 15: 326-33.
8. Duprez DA. Systolic hypertension in the elderly: addressing an unmet need. Am J Med 2008; 121: 179-84.
9. Wallace SML, Yasmin, McEniery CM, et al. Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction. Hypertension 2007; 50: 228-33.
10. Gates PE, Boucher ML, Silver AE, et al. Impaired flow-mediated dilation with age is not explained by L-arginine bioavailability or endothelial asymmetric dimethylarginine protein expression. J Appl Physiol 2007; 102: 63-71.
11. Campia U, Choucair WK, Bryant MB, et al. Reduced endotheliumdependent and -independent dilation of conductance arteries in African Americans. JACC 2002; 40: 754-60.
12. Kahn DF, Duffy SJ, Tomasiam D, et al. Effects of black race on forearm resistance vessel function. Hypertension 2002; 40: 195-201.
13. Taylor AA, Bakris GL. The role of vasodilating β-blockers in patients with hypertension and the cardiometabolic syndrome. Am J Med 2010;123: S21-6.
14. Shekelle PG, Rich MW, Morton SC, et al. Efficacy of angiotensinconverting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. JACC 2003; 41: 1529-38.
15. Prisant LM, Mensah GA. Use of β-adrenergic receptor blockers in blacks. J Clin Pharmacol 1996; 36: 867-73.
16. Dahlöf B, Devereux RB, Kjeldsen SE, et al, for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
17. Messerli FH, Grossman E, Goldbourt U. Are β-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279: 1903-7.
18. Douglas JG, Bakris GL, Epstein M, et al, for the Hypertension in African Americans Working Group. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society of Hypertension in Blacks. Arch Intern Med 2003; 163: 525-41.
19. Cushman WC, Reda DJ, Perry HM, et al. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Arch Intern Med 2000; 160: 825-31.
20. Preston RA, Materson BJ, Reda DJ, et al. Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. JAMA 1998; 280: 1168-72.
21. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914-21.
22. Sheats N, Lin Y, Zhao W, Cheek DE, Lackland DT, Egan BM. Prevalence, treatment, and control of hypertension among African Americans and Caucasians at primary care sites for medically underserved patients. Ethn Dis 2005; 15: 25-32.
23. Rehman SU, Hutchison FN, Hendrix K, et al. Ethnic differences in blood pressure control among men at Veterans Affairs clinics and other health care sites. Arch Intern Med 2005; 165: 1041-7.
24. Brewster LM, van Montfrans GA, Kleijnen J. Systematic review: antihypertension drug therapy in black patients. Ann Intern Med 2004; 141: 614-27.
25. Wright JT, Bakris G, Greene T, et al, for the African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-31.
26. Mason RP, Kalinowski L, Jacob RF, et al. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 2005; 112: 3795-801.
27. Cardillo C, Kilcoyne CM, Cannon RO III, Panza JA. Racial differences in nitric oxide-mediated vasodilator response to mental stress in the forearm circulation. Hypertension. 1998; 31: 1235-9.
28. Cardillo C, Kilcoyne CM, Cannon RO III, Panza JA. Attenuation of cyclic nucleotide-mediated smooth muscle relaxation in blacks as a cause of racial differences in vasodilator function. Circulation 1999; 99: 90-5.
29. Lang CC, Stein CM, He HB, et al. Blunted blood pressure response to central sympathoinhibition in normotensive blacks: increased importance of nonsympathetic factors in blood pressure maintenance in blacks. Hypertension 1997; 30: 157-62.
30. Saunders E, Weir MR, Kong BW, et al. A comparison of the efficacy and safety of a β-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990; 150: 1707-13.
31. Kamp O, Sieswerda GT, Visser CA. Comparison of effects of systolic and diastolic left ventricular function on nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol 2003; 92: 344-8.
32. Saunders E, Smith WB, DeSalvo KB, Sullivan WA. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich) 2007; 9: 866-75.
33. Dhakam Z, Yasmin, McEniery CM, et al. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens 2008; 26: 351-6.
34. McEniery CM, Schmitt M, Qasem A, et al. Nebivolol increases arterial distensibility in vivo. Hypertension 2004; 44: 305-10.
35. Cleophas TJ, Grabowsky I, Niemeyer MG, et al, for the Nebivolol Follow-up Study Group. Paradoxical pressor effects of β-blockers in standing elderly patients with mild hypertension: a beneficial side effect. Circulation 2002; 105: 1669-71.
36. Gradman AH. Safety and tolerability of nebivolol: a pooled safety analysis comparing typical β-blocker-associated adverse events with those of placebo. J Clin Hypertens (Greenwich) 2008; 10(suppl A): A120.
37. Mazza A, Gil-Extremera B, Maldonato A, et al. Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood Press 2002; 11: 182-8.
38. Flather MD, Shibata MC, Coats AJS, et al, for the SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-25.
